The Wyss Institute at Harvard Universtiy and Dana-Farber Cancer Institute have entered a licensing and collaboration agreement with Novartis to develop our biomaterial systems to delivery next generation immunotherapies. Our approach uses an injectable or implantable biomaterial scaffold that recruits and trains the body's endogenous immune cells to identify and kill a patient's own cancerous cells. A big congratulations to Dave...